Lipocine Inc. Files 8-K

Ticker: LPCN · Form: 8-K · Filed: Sep 5, 2025 · CIK: 1535955

Lipocine Inc. 8-K Filing Summary
FieldDetail
CompanyLipocine Inc. (LPCN)
Form Type8-K
Filed DateSep 5, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

Related Tickers: LPCN

TL;DR

LPCN filed an 8-K, check for updates.

AI Summary

Lipocine Inc. filed an 8-K on September 5, 2025, reporting on other events and financial statements. The filing does not detail specific transactions or financial results but serves as a routine update.

Why It Matters

This 8-K filing indicates Lipocine Inc. is providing updates to the SEC, which could include material information relevant to investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K without specific negative or positive disclosures, making the immediate risk level low.

Key Players & Entities

  • Lipocine Inc. (company) — Registrant
  • September 5, 2025 (date) — Date of Earliest Event Reported
  • 801-994-7383 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing for Lipocine Inc.?

This 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of September 5, 2025.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is September 5, 2025.

What is Lipocine Inc.'s commission file number?

Lipocine Inc.'s commission file number is 001-36357.

Where is Lipocine Inc.'s principal executive office located?

Lipocine Inc.'s principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

Has Lipocine Inc. had a former company name or address change reported in this filing?

No, the filing states 'Not Applicable' for former company name or address changes since the last report.

Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2025-09-05 10:53:41

Key Financial Figures

  • $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: September 5, 2025 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.